317 related articles for article (PubMed ID: 37237260)
21. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.
Perna A; Ruggiero B; Podestà MA; Perico L; Orisio S; Debiec H; Remuzzi G; Ruggenenti P
Front Pharmacol; 2022; 13():958136. PubMed ID: 36120314
[TBL] [Abstract][Full Text] [Related]
22. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
[TBL] [Abstract][Full Text] [Related]
23. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological Characteristics and Outcomes of PLA
Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
[TBL] [Abstract][Full Text] [Related]
25. Serum PLA2R antibody as a predictive biomarker for venous thromboembolism risk in primary membranous nephropathy.
Li J; Wang X; Jiang S; Li W
Med Clin (Barc); 2023 Nov; 161(10):417-421. PubMed ID: 37532619
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
27. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
28. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
Ramachandran R; Kumar V; Kumar A; Yadav AK; Nada R; Kumar H; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
Nephrol Dial Transplant; 2016 Sep; 31(9):1486-93. PubMed ID: 26673907
[TBL] [Abstract][Full Text] [Related]
29. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
30. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
31. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
32. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
[TBL] [Abstract][Full Text] [Related]
33. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
34. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
35. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy.
Barrett C; Willcocks LC; Jones RB; Tarzi RM; Henderson RB; Cai G; Gisbert SI; Belson AS; Savage CO
Nephrol Dial Transplant; 2020 Apr; 35(4):599-606. PubMed ID: 31243451
[TBL] [Abstract][Full Text] [Related]
36. [The 493th case: recurrent edema of bilateral lower extremeties].
Xie HY; Chen G; Li XM; Li X
Zhonghua Nei Ke Za Zhi; 2022 Mar; 61(3):355-358. PubMed ID: 35263982
[TBL] [Abstract][Full Text] [Related]
37. [The relationship between anti-phospholipase A2 receptor antibody and idiopathic membranous nephropathy].
Lin W; Li H; Li X; Qin Y; Su Y; Yu Y; Guan Y; Duan L; Li Y; Wen Y; Li X
Zhonghua Nei Ke Za Zhi; 2015 Sep; 54(9):783-8. PubMed ID: 26674797
[TBL] [Abstract][Full Text] [Related]
38. Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis.
Dong D; Fan TT; Wang YY; Zhang L; Song L; Zhang L
BMC Nephrol; 2019 Dec; 20(1):444. PubMed ID: 31791262
[TBL] [Abstract][Full Text] [Related]
39. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy.
Chen Y; Xu Y; Chen S; Yu Y; Zhu X; Chen J
Ren Fail; 2023; 45(2):2264939. PubMed ID: 37814415
[TBL] [Abstract][Full Text] [Related]
40. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD.
Hanset N; Esteve E; Plaisier E; Johanet C; Michel PA; Boffa JJ; Fievet P; Mesnard L; Morelle J; Ronco P; Dahan K
Kidney Int Rep; 2020 Mar; 5(3):331-338. PubMed ID: 32154454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]